Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)
Source: SeekingAlpha
2025-08-06 18:02:37 ET
In early to mid-2024, it appeared sales of Aurinia Pharmaceuticals Inc.'s ( AUPH ) Lupkynis might have topped out, and the stock was at lows below $5. When Q1 '24 earnings confirmed a resumption of sales growth in May 2024, I switched from Hold to a Buy , and the name is up about 117% since that article. I've continued to rate the name a Buy along the way, most recently in April 2025, anticipating sales of Lupkynis to continue to increase....
Read the full article on Seeking Alpha
For further details see:
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)
Otsuka Holdings Co. Ltd. ADR
NASDAQ: OTSKY
OTSKY Trading
-0.53% G/L:
$31.09 Last:
3,828 Volume:
$32.70 Open:
OTSKY Latest News
May 17, 2025 01:00:00 am
Innovations in High Blood Pressure Intervention Benefit Patients with Resistant Hypertension
February 06, 2025 02:00:00 pm
TANAKA to Provide Medals for the Tokyo Marathon 2025 That Represent All the Participants in the Event with Woven Lines
